Christian Dimaano, PhD

Christian brings over 15 years of industry experience in R&D and Medical Affairs to Kinnate. Christian’s expertise encompasses translational research, medical affairs, HEOR, patient advocacy, and public health. Most recently, Christian served as Head of Regional Medical Affairs at Mirati Therapeutics where he was responsible for building out and leading medical external engagement in support of the launch of adagrasib, a novel KRAS G12C inhibitor, in NSCLC. Over his career, Christian has held roles of increasing responsibility at Myriad Genetics, Bristol Myers Squibb, Gilead Sciences, Astellas, and Mirati Therapeutics - leading teams through multiple Oncology product launches including ERBITUX, OPDIVO, XTANDI, XOSPATA, PADCEV, and KRAZATI. Christian holds a PhD in Basic Science Oncology from the Huntsman Cancer Institute, an MPH from the University of Washington, and BS degree in Biology from the University of San Francisco. Christian is also clinical faculty at the University of Washington, sits on his local Board of the American Cancer Society, and serves as a STEM mentor with Biocom California.